Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

CGTX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 23.80%

Insider Buying (Last 12 Months): $9,975.00

Insider Selling (Last 12 Months): $0.00

Cognition Therapeutics Insider Trading History Chart

Cognition Therapeutics Share Price & Price History

^$1.95

▲ +0.02 (1.04%)

As of 04/26/2024 01:00 AM ET

Days: 30 | 90 | 365

The Best AI Stock to Own in the World Today is Trading for Just $25

From Banyan Hill Publishing | Ad

“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.

See how you can invest alongside him

Cognition Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/14/2024	Lisa Ricciardi	CEO	Buy	5,700	$1.75	$9,975.00	291,345
11/29/2022	Ellen B Richstone	Director	Buy	10,000	$2.65	$26,500.00	10,000
11/15/2022	Lisa Ricciardi	CEO	Buy	12,000	$1.30	$15,600.00	24,500
11/15/2022	Peggy Wallace	Director	Buy	12,500	$1.20	$15,000.00	37,961
10/13/2021	Peggy Wallace	Director	Buy	3,000	$12.00	$36,000.00

The Best AI Stock to Own in the World Today is Trading for Just $25

From Banyan Hill Publishing | Ad

See how you can invest alongside him

SEC Filings (Institutional Ownership Changes) for Cognition Therapeutics (NASDAQ:CGTX)

43.35% of Cognition Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Cognition Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
3/5/2024	Twin Focus Capital Partners LLC	93,372	$0.17M	0.0%	N/A	0.291%
2/8/2024	Texas Capital Bank Wealth Management Services Inc	55,395	$0.10M	0.0%	N/A	0.172%
2/1/2024	Sigma Planning Corp	28,550	$53K	0.0%	N/A	0.089%
10/23/2023	Steward Financial Group LLC	40,874	$58K	0.0%	N/A	0.135%
7/28/2023	Voss Capital LLC	60,222	$0.11M	0.0%	-62.4%	0.206%
5/12/2023	Voss Capital LLC	159,973	$0.32M	0.0%	-4.2%	0.546%
5/12/2023	FCA Corp TX	51,471	$0.10M	0.0%	N/A	0.176%
2/16/2023	AIGH Capital Management LLC	2,037,853	$4.28M	1.4%	+155.3%	7.030%
2/13/2023	Northeast Financial Consultants Inc	24,500	$51K	0.0%	N/A	0.085%
2/13/2023	Voss Capital LLC	166,903	$0.35M	0.1%	-23.8%	0.576%
2/13/2023	Financial Partners Capital Management LLC	14,228	$30K	0.0%	N/A	0.049%
2/7/2023	Commonwealth Equity Services LLC	189,307	$0.40M	0.0%	-13.6%	0.653%
2/6/2023	Neumann Capital Management LLC	33,382	$70K	0.0%	N/A	0.115%
1/31/2023	Kestra Advisory Services LLC	50,618	$0.11M	0.0%	+237.5%	0.175%
1/20/2023	Diligent Investors LLC	20,000	$42K	0.0%	-34.5%	0.069%
12/13/2022	Perigon Wealth Management LLC	36,900	$70K	0.0%	-70.0%	0.127%
11/15/2022	Carlson Capital L P	100,000	$0.19M	0.0%	N/A	0.440%
11/14/2022	Worth Venture Partners LLC	200,188	$0.38M	0.2%	-12.3%	0.881%
11/10/2022	Rock Creek Group LP	50,000	$95K	0.0%	-37.3%	0.220%
11/2/2022	Voss Capital LLC	219,100	$0.42M	0.1%	-29.2%	0.965%
11/1/2022	P.A.W. Capital Corp	100,000	$0.19M	0.3%	-25.9%	0.440%
10/12/2022	Wealth Alliance Advisory Group LLC	18,500	$35K	0.0%	N/A	0.081%
8/13/2022	Voss Capital LLC	309,472	$0.65M	0.2%	+1,070.5%	1.363%
8/13/2022	Prosight Management LP	120,198	$0.25M	0.2%	-49.9%	0.532%
8/11/2022	Perigon Wealth Management LLC	122,846	$0.26M	0.0%	N/A	0.544%
8/8/2022	Rock Creek Group LP	79,751	$0.17M	0.0%	+201.6%	0.353%
8/1/2022	Castle Wealth Management LLC	43,380	$92K	0.1%	N/A	0.192%
7/19/2022	Commonwealth Equity Services LLC	214,961	$0.45M	0.0%	+1,447.6%	0.951%
7/13/2022	P.A.W. Capital Corp	135,000	$0.29M	0.4%	+12.5%	0.597%
5/17/2022	Prosight Management LP	240,080	$0.66M	0.4%	-20.5%	1.062%
5/4/2022	Commonwealth Equity Services LLC	13,890	$38K	0.0%	N/A	0.061%
4/26/2022	Diligent Investors LLC	30,520	$84K	0.0%	N/A	0.135%
4/26/2022	Kestra Advisory Services LLC	238,666	$0.66M	0.0%	+150.9%	1.057%
4/21/2022	P.A.W. Capital Corp	120,000	$0.33M	0.3%	+20.0%	0.531%
4/14/2022	Bangor Savings Bank	18,496	$51K	0.0%	N/A	0.082%
2/10/2022	B. Riley Financial Inc.	30,904	$0.20M	0.0%	N/A	0.140%
2/10/2022	American Financial Group Inc.	205,000	$1.30M	0.4%	N/A	0.930%
2/10/2022	AIGH Capital Management LLC	25,496	$0.16M	0.0%	N/A	0.116%
2/10/2022	P.A.W. Capital Corp	100,000	$0.63M	0.6%	N/A	0.454%

Data available starting January 2016

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer's disease. The company is also developing COG0201 SHINE, a randomized double-blind and placebo-controlled for mild-to-moderate AD and is in phase II clinical trial. Its product pipeline also includes CT2168 for Synucleinopathies; and CT2074 for dry age-related macular degeneration. The company was incorporated in 2007 and is headquartered in Purchase, New York.

Today's Range

Now: $1.95

$1.87

$1.97

50 Day Range

MA: $1.93

$1.78

$2.10

52 Week Range

Now: $1.95

$0.90

$3.49

Volume

55,055 shs

Average Volume

194,601 shs

Market Capitalization

$76.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.63

Who are the company insiders with the largest holdings of Cognition Therapeutics?: Cognition Therapeutics' top insider investors include:
Lisa Ricciardi (CEO)
Peggy Wallace (Director)
Ellen B Richstone (Director)
Learn More about top insider investors at Cognition Therapeutics.